Longitudinal MRI study

The effects of azathioprine in MS patients refractory to interferon β-1b

S. Markovic-Plese, B. Bielekova, N. Kadom, T. P. Leist, R. Martin, J. A. Frank, H. F. McFarland

Research output: Contribution to journalArticle

Abstract

An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon β-1b (IFNβ-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNβ-1b-treated MS patients with continued disease activity were studied on IFNβ-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).

Original languageEnglish (US)
Pages (from-to)1849-1851
Number of pages3
JournalNeurology
Volume60
Issue number11
StatePublished - Jun 10 2003
Externally publishedYes

Fingerprint

Azathioprine
Interferons
Longitudinal Studies
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Markovic-Plese, S., Bielekova, B., Kadom, N., Leist, T. P., Martin, R., Frank, J. A., & McFarland, H. F. (2003). Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b. Neurology, 60(11), 1849-1851.

Longitudinal MRI study : The effects of azathioprine in MS patients refractory to interferon β-1b. / Markovic-Plese, S.; Bielekova, B.; Kadom, N.; Leist, T. P.; Martin, R.; Frank, J. A.; McFarland, H. F.

In: Neurology, Vol. 60, No. 11, 10.06.2003, p. 1849-1851.

Research output: Contribution to journalArticle

Markovic-Plese, S, Bielekova, B, Kadom, N, Leist, TP, Martin, R, Frank, JA & McFarland, HF 2003, 'Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b', Neurology, vol. 60, no. 11, pp. 1849-1851.
Markovic-Plese S, Bielekova B, Kadom N, Leist TP, Martin R, Frank JA et al. Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b. Neurology. 2003 Jun 10;60(11):1849-1851.
Markovic-Plese, S. ; Bielekova, B. ; Kadom, N. ; Leist, T. P. ; Martin, R. ; Frank, J. A. ; McFarland, H. F. / Longitudinal MRI study : The effects of azathioprine in MS patients refractory to interferon β-1b. In: Neurology. 2003 ; Vol. 60, No. 11. pp. 1849-1851.
@article{e3391aaf304444f89a7ec405a28f8df0,
title = "Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b",
abstract = "An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon β-1b (IFNβ-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNβ-1b-treated MS patients with continued disease activity were studied on IFNβ-1b and AZA therapy for a median period of 15 months. A 69{\%} reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).",
author = "S. Markovic-Plese and B. Bielekova and N. Kadom and Leist, {T. P.} and R. Martin and Frank, {J. A.} and McFarland, {H. F.}",
year = "2003",
month = "6",
day = "10",
language = "English (US)",
volume = "60",
pages = "1849--1851",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Longitudinal MRI study

T2 - The effects of azathioprine in MS patients refractory to interferon β-1b

AU - Markovic-Plese, S.

AU - Bielekova, B.

AU - Kadom, N.

AU - Leist, T. P.

AU - Martin, R.

AU - Frank, J. A.

AU - McFarland, H. F.

PY - 2003/6/10

Y1 - 2003/6/10

N2 - An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon β-1b (IFNβ-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNβ-1b-treated MS patients with continued disease activity were studied on IFNβ-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).

AB - An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon β-1b (IFNβ-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNβ-1b-treated MS patients with continued disease activity were studied on IFNβ-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).

UR - http://www.scopus.com/inward/record.url?scp=0038115303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038115303&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 1849

EP - 1851

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -